Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lantheus Holdings (LNTH)

Lantheus Holdings (LNTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,207,719
  • Shares Outstanding, K 69,527
  • Annual Sales, $ 1,296 M
  • Annual Income, $ 326,660 K
  • EBIT $ 481 M
  • EBITDA $ 545 M
  • 60-Month Beta 0.45
  • Price/Sales 4.79
  • Price/Cash Flow 13.24
  • Price/Book 5.26

Options Overview Details

View History
  • Implied Volatility 43.72% ( +1.19%)
  • Historical Volatility 44.10%
  • IV Percentile 46%
  • IV Rank 31.25%
  • IV High 72.67% on 10/29/24
  • IV Low 30.56% on 05/21/24
  • Put/Call Vol Ratio 0.46
  • Today's Volume 35
  • Volume Avg (30-Day) 366
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 11,905
  • Open Int (30-Day) 14,702

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.38
  • Number of Estimates 7
  • High Estimate 1.56
  • Low Estimate 1.29
  • Prior Year 1.59
  • Growth Rate Est. (year over year) -13.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.72 +3.47%
on 12/03/24
96.46 -6.98%
on 12/18/24
-0.79 (-0.88%)
since 11/22/24
3-Month
75.00 +19.63%
on 11/19/24
118.21 -24.10%
on 11/04/24
-21.64 (-19.43%)
since 09/23/24
52-Week
50.20 +78.74%
on 01/23/24
126.89 -29.29%
on 07/16/24
+30.13 (+50.57%)
since 12/22/23

Most Recent Stories

More News
Why Lantheus Holdings Stock Won Big on Wednesday

The stock of radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) was a standout in the healthcare sector on Hump Day. The company saw its share price improve by almost 9% at market close, thanks...

LNTH : 89.58 (+0.32%)
Lantheus Holdings, Inc. Authorizes $250 Million Stock Repurchase Program to Enhance Shareholder Value

Lantheus Holdings announces a $250 million stock buyback program to enhance shareholder value while pursuing growth opportunities.Quiver AI SummaryLantheus Holdings, Inc. has announced a stock repurchase...

LNTH : 89.58 (+0.32%)
Lantheus Announces Share Repurchase Program

LNTH : 89.58 (+0.32%)
Lantheus to Present at the Jefferies London Healthcare Conference

LNTH : 89.58 (+0.32%)
Lantheus Continues to Commend CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY’s Blockbuster Status for 2025

LNTH : 89.58 (+0.32%)
Lantheus Holdings: Q3 Earnings Snapshot

Lantheus Holdings: Q3 Earnings Snapshot

LNTH : 89.58 (+0.32%)
Lantheus Reports Third Quarter 2024 Financial Results

LNTH : 89.58 (+0.32%)
Lantheus Applauds CMS’ CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care

LNTH : 89.58 (+0.32%)
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time

LNTH : 89.58 (+0.32%)
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

/CNW/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However,...

ONCY : 0.8632 (+3.87%)
NVS : 97.25 (+0.14%)
LNTH : 89.58 (+0.32%)
STRO : 1.8700 (-0.53%)
ZYME : 13.78 (-2.55%)
ONC.TO : 1.23 (+3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations,...

See More

Key Turning Points

3rd Resistance Point 94.26
2nd Resistance Point 92.97
1st Resistance Point 91.13
Last Price 89.58
1st Support Level 88.00
2nd Support Level 86.72
3rd Support Level 84.87

See More

52-Week High 126.89
Fibonacci 61.8% 97.59
Last Price 89.58
Fibonacci 50% 88.54
Fibonacci 38.2% 79.50
52-Week Low 50.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar